Resveratrol Dismantles a Key Cancer Shield to Kill Gastric Tumor Cells

Gastric cancer remains one of the deadliest malignancies worldwide, partly because it is often diagnosed late and responds poorly to existing therapies. Identifying new molecular targets and natural compounds that can exploit cancer-specific vulnerabilities is therefore a high priority in oncology research.

This study focused on the mitochondrial deubiquitinase USP36 and its substrate SOD2 (superoxide dismutase 2), a key antioxidant enzyme. The researchers found that USP36 removes ubiquitin tags from SOD2, preventing its degradation and thereby keeping mitochondria functional and cancer cells alive. High USP36 and SOD2 expression was confirmed in clinical gastric cancer samples and cell lines, suggesting this axis actively drives tumor progression.

Resveratrol, a polyphenol abundant in grapes and red wine, was shown to disrupt the USP36-SOD2 interaction. By inhibiting USP36-mediated stabilization of SOD2, resveratrol destabilizes mitochondrial function and causes reactive oxygen species (ROS) to accumulate. This oxidative stress triggers two forms of programmed cell death simultaneously: autophagy (cellular self-digestion) and ferroptosis (iron-dependent oxidative cell death). In vitro assays confirmed significant reductions in cancer cell proliferation and migration, while xenograft mouse models demonstrated meaningful suppression of tumor growth in vivo.

The implications are notable for both cancer biology and longevity research. Ferroptosis and autophagy are increasingly recognized as important mechanisms in aging and cancer suppression. Resveratrol's ability to engage both pathways through a single mitochondrial axis suggests a mechanistically elegant anti-cancer strategy.

Caveats include reliance on cell lines and mouse models without clinical trial data, and the bioavailability of resveratrol in humans remains a known pharmacological challenge that could limit direct translation of these findings.